Dr. Weber on Rationale for the CheckMate-238 Trial in Melanoma

Dr. Weber on Rationale for the CheckMate-238 Trial in Melanoma

Publication date: Oct 08, 2019

Jeffrey S. Weber, MD, PhD, discusses the rationale behind the randomized, double-blind, phase III CheckMate-238 trial in resected stage III or IV melanoma.

Website: https://www.onclive.com

Twitter: https://twitter.com/OncLive

Facebook: https://www.facebook.com/OncLive/

LinkedIn: https://www.linkedin.com/company/onclive

Concepts Keywords
Antibodies Untreated metastatic melanoma
Checkmate Stage melanoma
Double Blind RTT
LinkedIn Medicine
Melanoma Clinical medicine
Nevel Cancer
Peptide Melanoma
Phase III Health
PhD B-Raf inhibitor
Relapse Antibodies
Symbolism
Vaccine
VIN

Semantics

Type Source Name
disease MESH Melanoma
disease DOID Melanoma
pathway BSID Melanoma
gene UNIPROT PDC
drug DRUGBANK Coenzyme M

Similar

Original Article

Leave a Comment

Your email address will not be published. Required fields are marked *